The National Institute for Health and Welfare (THL) has conducted a study of HPV vaccine administered to girls in the years 2013–2015. The study investigated whether the vaccine increases the risk of autoimmune disorders. There were approximately 241,000 subjects in all. Approximately half of them, or 56 percent, received the vaccine. HPV vaccine prevents HPV viral infection and the precursors of cervical cancer that it causes.
Tick-borne encephalitis (TBE) vaccine is given in the National Vaccination Program for all people over the age of tree who are long-term residents or resident in risk areas of the tick-borne encephalitis.
National Institute of Health and Welfare defines risk areas each year. Outside the risk areas you can take the vaccine at your own expense or it may be included in your occupational health care. The vaccine is recommended for people who spend plenty of time in nature in the risk areas. Tick-borne encephalitis fever occurs locally in continental Finland.
For the first time, it has been shown that vaccines against human papillomavirus (HPV) prevent malignant HPV-associated cancers in women. This was the finding of a Finnish-Swedish research team coordinated by the University of Tampere. The finding was based on registry monitoring of Finnish subjects in randomised HPV-vaccinated and control cohorts.
The national vaccination register of Finland shows that influenza vaccination coverage of children below three years of age improved by three percentage points this season. Influenza vaccination coverage for people 65 years of age and older also increased slightly and is currently at 48 per cent.